A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
← catalyst calendarNCT06680037 · readout in 469 d
Sponsored by TG Therapeutics, Inc. (industry) · TGTX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
100estimated
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-06 | actual | When the study began enrolling |
| Primary completion | 2027-12-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-01-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- B-cell Mediated Autoimmune Disorders
Intervention
- Drug: Azercabtagene zapreleucel (azer-cel)
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Dose-Limiting Toxicities (DLTs)
measured From Day 0 to Day 28
Permalink · TGTX's whole pipeline · Catalyst calendar · Every registered study · What changed